Abstracts Archive - Page 448 of 2605 - ACR Meeting Abstracts

Abstract Number: 1739 • ACR Convergence 2023
Mass Spectrometry Identified Rheumatoid Arthritis-Specific Modified Proteins and the Discovery of Antigen-Specific Hidden Autoantibodies
Khetam Ghannam¹, Marieluise Kirchner², Holger Bang³, Thomas Häupl⁴, Sarah Ohrndorf¹, Jan Zernicke¹, Ulrike Kuckelkorn⁵, Philipp Mertins⁶, Eugen Feist⁷ and Gerd Burmester⁸, ¹Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, ²Proteomics Platform at Max Delbrück Center for Molecular Medicine and Berlin Institute of Health (BIH), Berlin, Germany, ³Orgentec Diagnostika GmbH, Mainz, Germany, ⁴Helios Department of Rheumatology, Vogelsang-Gommern, Germany, ⁵Institute of Biochemistry, Berlin, Germany, ⁶Proteomics Platform at Max Delbrück Center for Molecular Medicine and Berlin Institute of Health (BIH), Berlin, Germany, ⁷Helios Department of Rheumatology and Clinical Immunology, Vogelsang-Gommern, Germany, ⁸Charité – Universitätsmedizin Berlin, Department of Rheumatology and Clinical Immunology, Berlin, Germany
Background/Purpose: Rheumatoid arthritis (RA) is a chronic and systemic autoimmune disease characterized by synovial inflammation and progressive joint destruction. Given the presumed pathophysiologic role of…
Abstract Number: 2293 • ACR Convergence 2023
Recurrent Intracellular Infections Cluster Together in Patients of SLE with Lymphopenia and Active Disease
Rudrarpan Chatterjee¹, Sarit Pattanaik², Durga P Misra¹, Vikas Agarwal¹, Able Lawrence¹, Ramnath Misra³ and Amita Aggarwal¹, ¹Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India, ²SCB Medical College and Hospital, Cuttack, Odisha, Cuttack, India, ³Kalinga Institute of Medical Sciences, KIIT University, Lucknow, India
Background/Purpose: Infections are a major cause of morbidity and mortality in systemic lupus erythematosus (SLE). We studied whether infections cluster together and which patients are…
Abstract Number: 1724 • ACR Convergence 2023
Human Embryonic Stem Cell-derived Mesenchymal Stem Cells Attenuates Experimental Pulmonary Fibrosis Through Mitochondria Transfer Mediated Anti-apoptotic and Immunomodulatory Effects
Hanna Lee¹, Suhee Kim², Mingyo Kim², Ok-Yi Jeong³ and Sang-Il Lee², ¹Department of Internal Medicine, Gyeongsang National University Changwon Hospital, Changwon, South Korea, ²Department of Internal Medicine and Institute of Health Science, Gyeongsang National University School of Medicine and Hospital, JinJu, South Korea, ³Division of Rheumatology, Department of Internal Medicine and Institute of Health Science, Gyeongsang National University School of Medicine and Gyeongsang National University Hospital, Jinju, South Korea
Background/Purpose: Interstitial lung disease (ILD) is a serious condition characterized by inflammation and fibrosis in the lung interstitium. The important subtypes of ILD include idiopathic…
Abstract Number: 2286 • ACR Convergence 2023
Systemic Lupus Erythematosus and Functional Work Disability: A Qualitative Perspective Using a Work Disability Prevention Approach
Aaron Howe¹, Anson Li², Kevon Jules², Jeremy Tan², Malek Sadek², Mahta Kakvan³, Vijay Chattu¹, Ali Bani-Fatemi¹, Dennisse Bonilla⁴, Wils Nielsen⁵, Nicole Anderson⁶, J. Antonio Avina-Zubieta⁷, Mary Fox⁸, William Shaw⁹, Derek Haaland¹⁰, Janet Pope¹¹, Paul R. Fortin¹², Kathleen Bingham⁴, Nathalie Rozenbojm⁴, Christine Peschken¹³, Jiandong Su⁴, Jennifer Reynolds¹⁴, Catherine Ivory¹⁵, Dafna Gladman¹⁶, Murray Urowitz¹⁷, Francisco Sanchez-Guerrero¹⁸, Lily Lim¹³, Stephanie Keeling¹⁹, Ana Soberanis¹, Patti Katz²⁰, Zahi Touma¹ and Behdin Nowrouzi-Kia¹, ¹University of Toronto, Toronto, ON, Canada, ²University of Toronto, Restore Lab, Toronto, ON, Canada, ³University Health Network, University of Toronto, Toronto, ON, Canada, ⁴University Health Network, Toronto, ON, Canada, ⁵University of Toronto, Markham, ON, Canada, ⁶Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, ⁷Arthritis Research Canada, Vancouver, BC, Canada, ⁸York University, Toronto, ON, Canada, ⁹University of Connecticut School of Medicine, Farmington, CT, ¹⁰The Waterside Clinic, Oro Medonte, ON, Canada, ¹¹University of Western Ontario, London, ON, Canada, ¹²Centre ARThrite - CHU de Québec - Université Laval, Quebec City, QC, Canada, ¹³University of Manitoba, Winnipeg, MB, Canada, ¹⁴University of British Columbia, Vancouver, BC, Canada, ¹⁵The Ottawa Hospital Research Institute, Ottawa, ON, Canada, ¹⁶Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada, ¹⁷Schroeder Arthritis Institute, Krembil Research Institute; University of Toronto Lupus Clinic; Division of Rheumatology, Toronto, ON, Canada, ¹⁸University Health Network/Sinai Health system, Toronto, ON, Canada, ¹⁹University of Alberta, Edmonton, AB, Canada, ²⁰University of California San Francisco, San Rafael, CA
Background/Purpose: Work participation meaningfully influences mental wellbeing, health-related quality of life, and disease-related outcomes in individuals with systematic lupus erythematosus (SLE). Previous studies estimate that…
Abstract Number: 1726 • ACR Convergence 2023
Therapeutic Effect of ICAM-1 Mimic on Experimental Axial Spondyloarthritis
Melissa Lim¹, Shaghayegh Foroozan², Zoya Qaiyum³, Michael Tang¹, Enoch Yau⁴ and Robert Inman¹, ¹University Health Network, Toronto, ON, Canada, ²University Health Network/University of Toronto, Toronto, ON, Canada, ³Krembil Research Institute, Toronto, ON, Canada, ⁴University of Toronto, Toronto, ON, Canada
Background/Purpose: Axial Spondyloarthritis (AxSpA) is a chronic inflammatory arthritis primarily affecting the axial skeleton and commonly coexists with gut and skin inflammation. Currently, patients with…
Abstract Number: 1733 • ACR Convergence 2023
Platelet-Derived Growth Factor Is a Mediator of Disease in an Animal Model of Rheumatoid-Associated Interstitial Lung Disease
Nozima Aripova¹, Michael Duryee¹, Amy Nelson¹, Carlos Hunter¹, Breanna Butler¹, Bryant England¹, Jill Poole¹, Geoffrey Thiele¹ and Ted R Mikuls², ¹University of Nebraska Medical Center, Omaha, NE, ²Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is a leading cause of mortality in RA with limited treatment options as well as lack of available…
Abstract Number: 2288 • ACR Convergence 2023
Scoping Literature Review and Focus Groups Interviews to Identify Candidate Domains for the SLE OMERACT Core Domain Set
Wils Nielsen¹, Vibeke Strand², Lee Simon³, Maya Desai⁴, Ioannis Parodis⁵, Alfred Kim⁶, Daniel Wallace⁷, Yashaar Chaichian⁸, Sandra Navarra⁹, Cynthia Aranow¹⁰, Meggan MacKay¹⁰, Kimberly Trotter¹¹, Oshrat Tayer-Shifman¹², Ali Duarte-Garcia¹³, Lai-Shan Tam¹⁴, Manuel Ugarte-Gil¹⁵, Guillermo Pons-Estel¹⁶, John Reynolds¹⁷, Mandana Nikpour¹⁸, Danae Papachristos¹⁹, Alberta Hoi²⁰, Alison Hendry²¹, Juanita Romero-Diaz²², Rosalind Ramsey-Goldman²³, Hanan Alrayes²⁴, Ibrahim Almaghlouth²⁵, Aarabi Thayaparan²⁶, Carolina Munoz-Grajales²⁷, Aaron Howe²⁸, Behdin Nowrouzi-Kia²⁸, Melanie Anderson²⁹, Dennisse Bonilla²⁹, Julian Thumboo³⁰, Marta Mosca³¹, Martin Aringer³², Sindhu Johnson³³, Aaron Drucker³⁴, Eric Morand³⁵, Ian Bruce³⁶ and Zahi Touma²⁸, ¹University of Toronto, Markham, ON, Canada, ²Stanford University, Portola Valley, CA, ³SDG LLC, West Newton, MA, ⁴OCAD University, Toronto, ON, Canada, ⁵Karolinska Institutet, Stockholm, Sweden, ⁶Washington University School of Medicine, St. Louis, MO, ⁷Cedars-Sinai/David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁸Stanford University, San Mateo, CA, ⁹University of Santo Tomas Hospital, Joint and Bone Center, Manila, Philippines, ¹⁰Feinstein Institutes for Medical Research, Manhasset, NY, ¹¹University of Chicago, Chicago, IL, ¹²Meir Medical Center, Raanana, Israel, ¹³Mayo Clinic, Rochester, MN, ¹⁴The Chinese University of Hong Kong, New Territories, China, ¹⁵Universidad Cientifica del Sur, Lima, Peru, ¹⁶RELESSAR, Rosario, Argentina, ¹⁷University of Birmingham, Birmingham, United Kingdom, ¹⁸The University of Melbourne at St. Vincent’s Hospital Melbourne, Departments of Medicine and Rheumatology, Melbourne, Australia, ¹⁹Mater Hospital, Brisbane, Australia, ²⁰Monash University, Department of Medicine, Sub-faculty of Clinical and Molecular Medicine, Melbourne, Australia, ²¹Te Whatu Ora, Counties Manukau District, Middlemore Hospital, Auckland, New Zealand, ²²Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ²³Northwestern University, Chicago, IL, ²⁴Riyadh Military - Prince Soltan Military Medical City ( PSMMC ) - Olaya, Riyadh, Saudi Arabia, ²⁵King Saud University, Riyadh, Saudi Arabia, ²⁶Schroeder Arthritis Institute, Krembil Research Institute, Markham, ON, Canada, ²⁷UHN/TWH, Toronto, ON, Canada, ²⁸University of Toronto, Toronto, ON, Canada, ²⁹University Health Network, Toronto, ON, Canada, ³⁰Singapore General Hospital; Duke-NUS Medical School, Singapore, Singapore, ³¹Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, ³²Faculty of Medicine TU Dresden, Dresden, Germany, ³³Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, ON, Canada, ³⁴Women's College Hospital, Toronto, ON, Canada, ³⁵Monash University, Centre for Inflammatory Diseases, Melbourne, Australia, ³⁶University of Manchester, Manchester, United Kingdom
Background/Purpose: We established the OMERACT SLE Working Group in 2021 which includes over 150 members representing over 25 countries and 5 continents to develop a…
Abstract Number: 1743 • ACR Convergence 2023
Individuals At-risk for and with Rheumatoid Arthritis Have Elevated Fecal Concentrations of Arthritogenic Subdoligranulum didolesgii Correlating with CCP3 Antibodies
Lyndsey Cole¹, Sucai Liu², Brendan Allen², Marie Feser³, Kristen Demoruelle³, kevin Deane³, Michael Holer³ and kristine Kuhn², ¹University of Colorado School of Medicine, Centennial, CO, ²University of Colorado School of Medicine, Aurora, CO, ³University of Colorado Anschutz Medical Campus, Aurora, CO
Background/Purpose: Our prior investigation identified a specific strain of Subdoligranulum didolesgii, S. dido7, to which dual IgA/IgG family plasmablast-derived monoclonal autoantibodies from individuals at-risk for…
Abstract Number: 1735 • ACR Convergence 2023
An Unorthodox HLA-DRhiCD15+ ‘Hybrid’ Population in Rheumatoid Arthritis Characterized Using Spectral Cytometry
Christian Geier¹, Haani Qudsi², Jihad BenGabr¹, Robert Winchester³ and Andras Perl⁴, ¹SUNY Upstate Medical University, Syracuse, NY, ²Norton College of Medicine, SUNY Upstate Medical University, Syracuse, NY, ³Columbia University, New York, NY, ⁴SUNY, Syracuse, NY
Background/Purpose: A variant of HLA-DR confers the strongest genetic risk for rheumatoid arthritis (RA) suggesting that DRhi cells are important in RA. We previously found…
Abstract Number: 1695 • ACR Convergence 2023
Single Cell Transcriptomics in Kidney Tissue from African American Patients Enrolled in the Accelerating Medicines Partnership (AMP) Implicates Tubular Cells in the Pathogenesis of APOL1 Associated Lupus Nephritis
Philip Carlucci¹, Jasmine Shwetar², Siddarth Gurajala³, Qian Xiao³, Joseph Mears⁴, Katie Preisinger¹, Devyn Zaminski⁵, Kristina Deonaraine¹, Peter Izmirly¹, Andrea Fava⁶, Judith James⁷, Joel Guthridge⁷, Brad Rovin⁸, Sethu Madhavan⁸, Wade DeJager⁷, David Wofsy⁹, Ming Wu², Chaim Putterman¹⁰, Deepak Rao¹¹, Betty Diamond¹², Derek Fine¹³, Jose Monroy-Trujillo¹³, Kristin Haag¹⁴, H Michael Belmont⁵, William Apruzzese¹¹, Anne Davidson¹², Fernanda Payan-Schober¹⁵, Richard Furie¹⁶, Paul Hoover¹¹, Celine Berthier¹⁷, Maria Dall'Era⁹, Kerry Cho¹⁸, Diane L. Kamen¹⁹, Kenneth Kalunian²⁰, Jennifer Anolik²¹, Arnon Arazi²², Soumya Raychaudhuri¹¹, Nir Hacohen²³, Michelle Petri²⁴, Robert Clancy²⁵, Kelly Ruggles², Jill Buyon²⁵ and The Accelerating Medicines Partnership in RA/SLE²⁶, ¹New York University School of Medicine, New York, NY, ²NYU Langone, New York, NY, ³Harvard Medical School, Boston, MA, ⁴Michigan University, Ann Arbor, MI, ⁵NYU School of Medicine, New York, NY, ⁶Johns Hopkins University, Baltimore, MD, ⁷Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁸Ohio State University, Columbus, OH, ⁹University of California San Francisco, San Francisco, CA, ¹⁰Albert Einstein College of Medicine, Bronx, NY, ¹¹Brigham and Women's Hospital, Boston, MA, ¹²Feinstein Institutes for Medical Research, Manhasset, NY, ¹³Johns Hopkins School of Medicine, Baltimore, MD, ¹⁴Thomas Jefferson University, Philadelphia, PA, ¹⁵Texas Tech University Health Sciences Center, El Paso, TX, ¹⁶Northwell Health, Manhasset, NY, ¹⁷University of Michigan, Ann Arbor, MI, ¹⁸UCSF Health, San Francisco, CA, ¹⁹Medical University of South Carolina, Charleston, SC, ²⁰University of California San Diego, La Jolla, CA, ²¹University of Rochester Medical Center, Rochester, NY, ²²Broad Institute of MIT and Harvard, Melrose, MA, ²³Broad Institute of MIT and Harvard, Cambridge, MA, ²⁴Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, ²⁵NYU Grossman School of Medicine, New York, NY, ²⁶Multiple, Bethesda, MD
Background/Purpose: The G1 and G2 risk variants (RVs) in Apolipoprotein L1 (APOL1) associate with CKD and may contribute to poorer outcomes for African American (AA)…
Abstract Number: 1679 • ACR Convergence 2023
Effects of Janus Kinase Inhibitor on TNF-a and IL-6-Induced Osteoclasts and RANKL-Induced Osteoclasts in Peripheral Blood Monocytes from Patients with Rheumatoid Arthritis
Kazuhiro Yokota¹, Yoshimi Aizaki², Takuma Tsuzuki Wada¹, Hiroshi Kajiyama¹, Yasuto Araki², Hiroaki Yazawa², Yuji Akiyama² and Toshihide Mimura¹, ¹Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Iruma-gun, Japan, ²Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan
Background/Purpose: We have previously demonstrated that a combination of TNF-a and IL-6 induces mouse osteoclast-like cells with bone resorption activity both in vitro and in…
Abstract Number: 1681 • ACR Convergence 2023
Tacrolimus Use in SLE Pregnancy and Its Effect on Pregnancy Outcomes: Retrospective Study in Two Japanese Tertiary Referral Centers
Takehiro Nakai¹, Nanase Honda², Eri Soga², Sho Fukui³, Ayako Kitada¹, Naoto Yokogawa⁴ and Masato Okada¹, ¹St. Luke's International Hospital, Tokyo, Japan, ²Tokyo Metropolitan Tama Medical Center, Tama, Japan, ³Brigham and Women's Hospital, Boston, MA, ⁴Tokyo Metropolitan Tama Medical Center, Taito City, Tokyo, Japan
Background/Purpose: Tacrolimus is one of the major treatment options of systemic lupus erythematosus (SLE) and is thought to be pregnancy compatible medication. Since little is…
Abstract Number: 1260 • ACR Convergence 2023
Optimal Approaches for Reducing Depressive Symptoms in Rheumatoid Arthritis Patients Based on Psychological Interventions: A Systematic Review and Network Meta-analysis
Zhang Lijuan and Wu Beiwen, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Background/Purpose: In recent years, numerous psychological interventions for rheumatoid arthritis (RA) patients have been developed. However, it remains unclear which psychological interventions are effective and…
Abstract Number: 1682 • ACR Convergence 2023
Prospective Evaluation of Anti-SSA/Ro Pregnancies Supports the Utility of High Titer Antibodies and Fetal Home Monitoring for the Detection of Fetal Atrioventricular Block
Bettina Cuneo¹, Mala Masson², Colin Phoon³, Ashley Roman³, Peter Izmirly⁴, Amit Saxena⁵, Michael Belmont⁶, Christina Penfield³, Young Mi Lee³, Julie Nusbaum⁷, Ruben Acherman⁸, Elena Sinkovskaya⁹, Alfred Abuhamad¹⁰, Majd Makhoul¹¹, Gary Satou¹², Whitnee Hogan¹³, Nelangi Pinto¹³, Anita Moon-Grady¹⁴, Lisa Howley¹⁵, Mary Donofrio¹⁶, Anita Krishnan¹⁶, Homa Ahmadzia¹⁷, Stephanie Levasseur¹⁸, Erin Paul¹⁹, Sonal Owens²⁰, Kristopher Cumberback²¹, Jyothi Matta²², Gary Joffe²³, Christopher Lindblade²⁴, Andrew Rubenstein²⁵, Caitlin Haxel²⁶, Katherine Kohari²⁷, Joshua Copel²⁷, James Strainic²⁸, Tam Doan²⁹, Karla Bermudez-Wagner²⁹, Shreya Sheth²⁹, Stacy Killen³⁰, Theresa Tacy³¹, Michelle Kaplinski³¹, Lisa Hornberger³², Nicola Fraser³, Robert Clancy³ and Jill Buyon³³, ¹University of Colorado, Denver, Denver, CO, ²New York University, New York, NY, ³NYU Grossman School of Medicine, New York, NY, ⁴New York University School of Medicine, New York, NY, ⁵NYU Langone, New York, NY, ⁶New York University Langone Medical Center, New York, NY, ⁷NYU Long Island School of Medicine, Mineola, NY, ⁸Children's Heart Center, Las Vegas, NV, ⁹East Virginia Medical School, East Virginia Medical School, VA, ¹⁰East Virginia Medical School, Norfolk, VA, ¹¹Atrium Health Levine Children's Hospital, Charlotte, NC, ¹²University of California Los Angeles, Los Angeles, CA, ¹³University of Utah, Salt Lake City, UT, ¹⁴University of California San Francisco, San Francisco, CA, ¹⁵Midwest Fetal Care Center, Children's Minnesota/Allina Health, Minneapolis, MN, ¹⁶Children's National Hospital, Washington, DC, ¹⁷George Washington University, Washington, DC, ¹⁸Columbia University, New York, NY, ¹⁹Mount Sinai, New York, NY, ²⁰University of Michigan, Ann Arbor, MI, ²¹University of Kentucky, Lexington, KY, ²²University of Louisville, Louisville, KY, ²³Perinatal Associates of New Mexico, Albuquerque, NM, ²⁴Phoenix Children's Hospital, Phoenix, AZ, ²⁵Dignity Health, Phoenix, AZ, ²⁶University of Vermont Children's Hospital, Burlington, VT, ²⁷Yale University, New Haven, CT, ²⁸UH Rainbow Babies, Cleveland, OH, ²⁹Baylor School of Medicine, Houston, TX, ³⁰Vanderbilt University, Nashville, TN, ³¹Stanford University, Stanford, CA, ³²Stollery Children's Hospital, Edmonton, AB, Canada, ³³Department of Medicine, NYU Grossman School of Medicine, New York, NY
Background/Purpose: The management of fetuses exposed to maternal anti-SSA/Ro autoantibodies is challenging as the clinician weighs the rarity of fetal atrioventricular block (AVB) against the…
Abstract Number: 1694 • ACR Convergence 2023
Transcriptomic Analysis of the Impact of Iberdomide on Patients with SLE
Prathyusha Bachali¹, Shimon Korish², Yanhua Hu³, Peter Schafer⁴, Amrie Grammer¹ and Peter Lipsky¹, ¹AMPEL BioSolutions, Charlottesville, VA, ²Bristol Myers Squibb, Summit, NJ, ³Bristol Myers Squibb, Princeton, NJ, ⁴Bristol Myers Squibb, Belle Mead, NJ
Background/Purpose: Iberdomide is a high affinity cereblon ligand that promotes ubiquitylation and proteasomal degradation of Ikaros (IKZF1) and Aiolos (IKZF3) transcription factors and, thereby altering…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].